JB Chemicals and Pharmaceuticals Ltd., has emerged as the fastest growing pharmaceuticals company amongst the top twenty five companies in the Indian Pharmaceutical Market during the Financial Year 2021-22 registering an impressive growth rate of 29% outperforming the market rate of 18% as per the moving annual turnover (MAT) basis in March 2022, JB Chemicals and Pharmaceuticals informed in a statement.
“More so, 5 brands of JBCPL are ranked in the top 300 pharmaceutical brands of the Indian Pharmaceutical Market,” the company said.
Mr Nikhil Chopra, CEO & Whole Time Director, JBCPL said, “We have made a remarkable growth during the financial year 2021-22. Though currently, we are ranked 25 in the Indian Pharmaceutical Market, we target to have the company rank in the top 20 pharmaceutical firms. We have outperformed in the cardiac segment with 3 of its brands marking their presence in the top 300 brands of Indian Pharmaceutical Market.”
As per the statement of the JB Chemicals and Pharmaceuticals, JB sales as per IQVIA MAT 22 was at INR 1490.7 crores as compared to INR 1157.4 crores a year back recording growth of 28.8 % for FY 22. JB was the fastest growing pharmaceutical company in FY 2021-22.
“The second fastest growing pharma company among the top 25 as per IQVIA is Alkem which recorded sales as per IQVIA MAT 22 at INR 7244 crores as compared to INR 5676 crores growing at 27.6 % for the financial year. The third fastest growing pharma company among the top 25 as per IQVIA is ARISTO which recorded sales as per IQVIA MAT 22 at INR 5459 crores as compared to INR 4352 crores growing at 25.4 % for the financial year,” the company added.
“We are delighted to be the fastest-growing company in the FY 2021-22. This has been possible because of the continued focus on its core therapy areas. Further, this growth has been achieved with an insignificant contribution from the COVID portfolio, which reflects the underlying growth momentum of our core business," Mr Dilip Singh Rathore, President, Domestic Business, JBCPL said.
"We remain confident that we will continue to outperform the Indian Pharmaceutical Market (IPM), and drive growth by focusing on our core therapy areas. Last year, we focused on building capabilities and focused on building a culture that will drive growth. We reached out to every employee to build a cohesive culture,” he further said.